ACM
ARRY

Atika Capital Management’s Array Biopharma Inc ARRY Stock Holding History

Atika Capital Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-175,000
Closed -$1.56M – 94
2017
Q1 		$1.56M Sell
175,000
-15,000
-8% -$160K 0.77% 50
2016
Q4 		$1.67M Buy
190,000
+63,000
+50% +$464K 0.99% 42
2016
Q3 		$857K Buy
+127,000
New +$491K 0.35% 63

Other funds holding ARRY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Atika Capital Management's ARRY Position: Q2 2017 in Review

Atika Capital Management sold out of Array Biopharma Inc (ARRY) in Q2 2017, closing a stake of 175,000 shares — an estimated $1.56M sold.

Atika Capital Management first reported a position in ARRY in Q3 2016 and held it in 3 quarters. The position peaked at $1.67M in Q4 2016. 182 funds tracked by Wall St. Rank hold ARRY as of Q2 2017.

  • Atika Capital Management reported no remaining Array Biopharma Inc position as of Q2 2017 after selling out during the quarter.
  • Atika Capital Management sold 175,000 Array Biopharma Inc shares in Q2 2017, an estimated $1.56M.
  • Atika Capital Management first reported a position in Array Biopharma Inc in Q3 2016 and held it in 3 quarters.
  • Atika Capital Management's Array Biopharma Inc position peaked at $1.67M in Q4 2016.
  • 182 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2017.

Based on Atika Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.